This is the latest speculative ASX tech buy from Citigroup

If you are on the hunt for the next shooting star in the small-cap tech sector, Citigroup may have just the trick for you.

| More on:
Investor with palm up and graphic illustration of asx small cap tech shares charts shooting from his hand

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you are on the hunt for the next shooting star in the small-cap tech sector, Citigroup may have just the trick for you.

Appetite for such stocks is strong after Brainchip Holdings Ltd (ASX: BRN) share price, Pointerra Ltd (ASX:3DP) share price and Tesserent Ltd (ASX: TNT) shot out the lights in 2020.

These stocks gained more than 700% over the past 12 months when the S&P/ASX 200 Index (Index:^AXJO) is standing at breakeven at best.

Big rewards and risks for this ASX small cap tech stock

If you want big rewards, you have to be prepared to stomach big risks. On that front, Citigroup reckons the Control Bionics Ltd (ASX: CBL) could be worth a punt.

The broker just initiated coverage on the CBL share price and slapped a "speculative buy" recommendation on it.

Control Bionics makes a wearable device that helps the disabled operate and communicate via a computer using only neural or visual signals.

Does CBL have a competitive advantage?

The company's technology, called NeuroNode, has an edge over the competition. Traditional systems use the movement of an arm or finger to activate a keyboard. Other visual/neural devices are harder to use and isn't as flexible.

"CBL has received regulatory clearance for the NeuroNode technology in key regions of US, Australia, Canada and Europe," explained Citi.

"A key target market is Japan and steps are in progress to secure relevant approvals."

Key revenue driver

Another noteworthy point is that Control Bionics is an approved provider under the National Disability Insurance Scheme (NDIS).

It is also approved by the US Veterans' Administration and Medicaid (in most states) as well as relationships with several private payors.

Around 78% of its revenues come from health insurers, according to Citi. That is a good thing as it makes the device accessible to the masses.

What is the CBL share price worth?

Control Bionics raised $15 million from its initial public offer in December last year as it sold shares at 60 cents a piece.

Those who jumped in have plenty to smile about as the CBL share price is currently trading at 97 cents.

But Citi believes it could go a lot higher in 2021 as it has a 12-month price target of $1.42 a share.

This leaves a lot of the profit on the table, but just remember that small cap tech stocks aren't for the fainthearted.

Brendon Lau has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Pointerra Limited. The Motley Fool Australia owns shares of CBL Limited. The Motley Fool Australia has recommended Pointerra Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors sent the market higher once again today.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Opinions

2 ASX shares I'd buy if the ASX crashes again

I think the best opportunities can be found when the market falls.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Share Market News

These ASX 200 stocks could rise 20% to 35%

These shares could be destined to deliver big returns over the next 12 months according to analysts.

Read more »

View of a mine site.
Broker Notes

How much upside does Macquarie tip for Deterra Royalties shares?

Deterra Royalties offers ASX investors a different way to invest in global mining.

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Gold

3 reasons to buy this surging ASX All Ords gold stock today

The ASX All Ords gold stock has doubled investors’ money in 12 months, and this leading expert forecasts more outperformance…

Read more »

Woman with $50 notes in her hand thinking, symbolising dividends.
Broker Notes

Broker reveals outlook for ASX dividend shares amid volatile market

Peter Gardner from Plato Investment Management tells ASX investors where to look for dividend income this year.

Read more »

Two colleagues at work looking at a tablet and smiling at a rising share price.
Share Gainers

Why Generation Development, Orica, Pro Medicus, and Zip shares are storming higher today

These shares are having a strong session on Thursday. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why ANZ, Brainchip, Light & Wonder, and Pilbara Minerals shares are falling today

These shares are tumbling on Thursday. But why?

Read more »